A bottom-up approach identifies the antipsychotic and antineoplastic trifluoperazine and the ribose derivative deoxytubercidin as novel microglial phagocytosis inhibitors.
Noelia Rodríguez-IglesiasiD, Iñaki ParisiD, Jorge ValeroiD, Lorena Cañas‐ZabalaiD, Alejandro Carretero, Klas HatjeiD, Jitao David ZhangiD, Christoph PatschiD, Markus BritschgiiD, Simon GutbieriD, Amanda SierraiD
Abstract
Phagocytosis is an indispensable function of microglia, the brain professional phagocytes. Microglia are particularly efficient phagocytosing cells that undergo programmed cell death (apoptosis) in physiological conditions. However, mounting evidence suggests microglial phagocytosis dysfunction in multiple brain disorders. These observations prompted us to search for phagocytosis modulators (enhancers or inhibitors) with therapeutic potential. We used a bottom-up strategy that consisted on the identification of phagocytosis modulators using phenotypic high throughput screenings (HTSs) in cell culture and validation in organotypic cultures and in vivo. We performed two complementary HTS campagnes: at Achucarro, we used primary cultures of mouse microglia and compounds of the Prestwick Chemical Library; at Roche, we used human iPSC derived macrophage-like cells and a proprietary chemo-genomic library with 2,200 compounds with known mechanism-of-action. Next, we validated the more robust compounds using hippocampal organotypic cultures and identified two hits: trifluoperazine, a dopaminergic and adrenergic antagonist used as an antipsychotic and antineoplastic; and deoxytubercidin, a ribose derivative. Finally, we tested whether these compounds were able to modulate phagocytosis of apoptotic newborn cells in the adult hippocampal neurogenic niche in vivo by administering them into the mouse hippocampus using osmotic minipumps. We confirmed that both trifluoperazine and deoxytubercidin have anti-phagocytic activity in vivo, and validated our bottom-up strategy to identify novel phagocytosis modulators. These results show that chemical libraries with anotated mechanism of action are an starting point for the pharmacological modulation of microglia in drug discovery projects aiming at the therapeutic manipulation of phagocytosis in brain diseases. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=194 SRC="FIGDIR/small/599284v1_ufig1.gif" ALT="Figure 1"> View larger version (49K): org.highwire.dtl.DTLVardef@13ed994org.highwire.dtl.DTLVardef@13ea710org.highwire.dtl.DTLVardef@4a1c7dorg.highwire.dtl.DTLVardef@1945f00_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 0.31
- Field percentile
- top 45%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identifying brain-penetrant small molecule modulators of human microglia using a cellular model of synaptic pruning
Liam T. McCrea, Rebecca Batorsky, … Steven D. Sheridan·NeuropsychopharmacologyPeer-reviewed·May 9, 2025
- Microglial low-affinity FcγR mediates the phagocytic elimination of dopaminergic neurons in Parkinsons disease degeneration
Paola V. Casanova, Irina Freitag-Berenguel, … Carlos Barcia·npj Parkinson s DiseasePeer-reviewed·Jan 16, 2026
- Controlling astrocyte-mediated synaptic pruning signals for schizophrenia drug repurposing with Deep Graph Networks
Alessio Gravina, Jennifer L. Wilson, … Corrado Priami·PLoS Computational BiologyPeer-reviewed·May 4, 2022
- Metabolic and transcriptional adaptations to phagocytosis in microglia sustain their functionality and regenerative properties
Mar Márquez-Ropero, Jorge Valero, … Amanda Sierra·bioRxiv·Sep 18, 2025
- Novel Master Regulators of Microglial Phagocytosis and Repurposed FDA-approved Drug for Treatment of Alzheimer Disease
Kuixi Zhu, Qianying He, … Rui R. Chang·bioRxiv·Oct 19, 2022
- Increasing phagocytosis of microglia through targeting CD33 with liposomes displaying glycan ligands
A. Bhattacherjee, G. Daskhan, … M. S. Macauley·bioRxiv·May 8, 2021